These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
416 related articles for article (PubMed ID: 22297548)
1. RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer. Sebova K; Zmetakova I; Bella V; Kajo K; Stankovicova I; Kajabova V; Krivulcik T; Lasabova Z; Tomka M; Galbavy S; Fridrichova I Cancer Biomark; 2011-2012; 10(1):13-26. PubMed ID: 22297548 [TBL] [Abstract][Full Text] [Related]
2. Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Shinozaki M; Hoon DS; Giuliano AE; Hansen NM; Wang HJ; Turner R; Taback B Clin Cancer Res; 2005 Mar; 11(6):2156-62. PubMed ID: 15788661 [TBL] [Abstract][Full Text] [Related]
3. Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA. Ahmed IA; Pusch CM; Hamed T; Rashad H; Idris A; El-Fadle AA; Blin N Cancer Genet Cytogenet; 2010 Jun; 199(2):96-100. PubMed ID: 20471512 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of protein expression and DNA methylation profiles detected by pyrosequencing in invasive breast cancer. Zmetakova I; Danihel L; Smolkova B; Mego M; Kajabova V; Krivulcik T; Rusnak I; Rychly B; Danis D; Repiska V; Blasko P; Karaba M; Benca J; Pechan J; Fridrichova I Neoplasma; 2013; 60(6):635-46. PubMed ID: 23906298 [TBL] [Abstract][Full Text] [Related]
5. Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARĪ²2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay. Yamamoto N; Nakayama T; Kajita M; Miyake T; Iwamoto T; Kim SJ; Sakai A; Ishihara H; Tamaki Y; Noguchi S Breast Cancer Res Treat; 2012 Feb; 132(1):165-73. PubMed ID: 21594664 [TBL] [Abstract][Full Text] [Related]
6. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Dulaimi E; Hillinck J; Ibanez de Caceres I; Al-Saleem T; Cairns P Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6189-93. PubMed ID: 15448006 [TBL] [Abstract][Full Text] [Related]
7. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients. Honorio S; Agathanggelou A; Schuermann M; Pankow W; Viacava P; Maher ER; Latif F Oncogene; 2003 Jan; 22(1):147-50. PubMed ID: 12527916 [TBL] [Abstract][Full Text] [Related]
8. CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer. Caldeira JR; Prando EC; Quevedo FC; Neto FA; Rainho CA; Rogatto SR BMC Cancer; 2006 Mar; 6():48. PubMed ID: 16512896 [TBL] [Abstract][Full Text] [Related]
10. Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only. De Schutter H; Geeraerts H; Verbeken E; Nuyts S Oncol Rep; 2009 Feb; 21(2):507-13. PubMed ID: 19148529 [TBL] [Abstract][Full Text] [Related]
11. Tumor-derived aberrant methylation in plasma of invasive ductal breast cancer patients: clinical implications. Hu XC; Wong IH; Chow LW Oncol Rep; 2003; 10(6):1811-5. PubMed ID: 14534701 [TBL] [Abstract][Full Text] [Related]
12. Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in testicular tumours and distinct methylation profiles of seminoma and nonseminoma testicular germ cell tumours. Honorio S; Agathanggelou A; Wernert N; Rothe M; Maher ER; Latif F Oncogene; 2003 Jan; 22(3):461-6. PubMed ID: 12545168 [TBL] [Abstract][Full Text] [Related]
13. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer. Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007 [TBL] [Abstract][Full Text] [Related]
14. Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients. Sharma G; Mirza S; Parshad R; Srivastava A; Gupta SD; Pandya P; Ralhan R Life Sci; 2010 Jul; 87(3-4):83-91. PubMed ID: 20470789 [TBL] [Abstract][Full Text] [Related]
15. Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer. Wang Y; Yu Z; Wang T; Zhang J; Hong L; Chen L Lung Cancer; 2007 May; 56(2):289-94. PubMed ID: 17267069 [TBL] [Abstract][Full Text] [Related]
16. Hypermethylation-modulated downregulation of RASSF1A expression is associated with the progression of esophageal cancer. Mao WM; Li P; Zheng QQ; Wang CC; Ge MH; Hu FJ; Fang XH; Dong ZM; Ling ZQ Arch Med Res; 2011 Apr; 42(3):182-8. PubMed ID: 21722812 [TBL] [Abstract][Full Text] [Related]
17. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions. Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681 [TBL] [Abstract][Full Text] [Related]
18. Investigation of tumor-derived extracellular DNA in blood of cancer patients by methylation-specific PCR. Rykova EY; Skvortsova TE; Laktionov PP; Tamkovich SN; Bryzgunova OE; Starikov AV; Kuznetsova NP; Kolomiets SA; Sevostianova NV; Vlassov VV Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(6-7):855-9. PubMed ID: 15560072 [TBL] [Abstract][Full Text] [Related]
19. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. Hoque MO; Begum S; Topaloglu O; Chatterjee A; Rosenbaum E; Van Criekinge W; Westra WH; Schoenberg M; Zahurak M; Goodman SN; Sidransky D J Natl Cancer Inst; 2006 Jul; 98(14):996-1004. PubMed ID: 16849682 [TBL] [Abstract][Full Text] [Related]
20. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma. Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]